Community post

Adaptive Phage Therapeutics announced that the first patient has been dosed in its DFO Adaptive Novel Care Evaluation (DANCE™) trial, a Phase 1/2 clinical study to evaluate the safety and efficacy of APT’s precision phage therapy in patients with Diabetic Foot Osteomyelitis.